Aurinia Pharmaceuticals Engages at London Conference

Aurinia Pharmaceuticals (AUPH) has released an update.

Aurinia Pharmaceuticals is set to participate in the Jefferies London Healthcare Conference, engaging with investors through one-on-one meetings and a fireside chat. The company, known for its FDA-approved treatment for lupus nephritis, continues to advance its pipeline with promising therapies for autoimmune diseases.

For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.